Clinical development of ZW171 to be discontinued in gynecological, thoracic, and digestive system cancers September 3, 2025
FDA granted Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for Patients with KRAS G12C-Mutated Cancers September 3, 2025
ATG-022 Granted Breakthrough Therapy Designation for the Treatment of Gastric/GEJ Adenocarcinoma August 26, 2025
First Patient Dosed in Pivotal Ph 3 Trial of Cadonilimab for Perioperative Treatment of Resectable Gastric Cancer August 26, 2025
Premarket approval (PMA) application submitted to FDA for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer August 26, 2025
FDA clears IND application of 7MW4911 to initiate Ph 1/2 trial in patients with advanced CRC and other advanced gastrointestinal tumors August 26, 2025
CTMX-2051-101 study remains active and patients continue to be dosed with CX-2051 across all expansion doses August 19, 2025
ELI-002 Updated AMPLIFY-201 Ph 1 Follow-up Data published in Nature Medicine for MRD Positive, Adjuvant-Stage Patients August 19, 2025
German federal authority approves CTA to initiate Ph 1/2a trial of CC-38 in patients with metastatic CRC and metastatic prostate cancer August 19, 2025
Positive Recommendation by IDMC Announced: ELI-002 7P Ph 2 Study in Pancreatic Cancer to Continue Without Modifications to Final Analysis August 12, 2025
Ph 1b trial of elraglusib, retifanlimab, and mFOLFIRINOX combo as 1L therapy in advanced pancreatic adenocarcinoma initiated August 12, 2025
Mid-year report of Ampligen® (rintatolimod) & Imfinzi® combo in pancreatic cancer demonstrates no significant toxicity and superior PFS and OS August 12, 2025
FDA & NMPA’s approval to initiate Ph 2 COMPASSION-36/AK104-225 registrational trial of cadonilimab + lenvatinib combo in IO-refractory HCC announced August 11, 2025
Positive Data Announced from Ph 2 CRDF-004 trial of onvansertib in 1L RAS-mutated mCRC August 5, 2025
NMPA and FDA approve initiation of Ph 2 trial (COMPASSION-36/AK104-225) of cadonilimab combo in previously treated HCC patients August 5, 2025
FDA Clears IND application for Ph 1/2 Trial of ABT-301 Triplet Therapy for Advanced CRC August 5, 2025
Imfinzi granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and GEJ cancers July 29, 2025
Positive Mid-year Safety and Efficacy Data from Ph 2 Study of Ampligen® (rintatolimod) + Imfinzi Combo for the Treatment of Pancreatic Cancer Reported July 29, 2025
